NEW YORK (GenomeWeb) – British research tools maker Abcam announced today that it has signed an agreement to acquire Cambridge, Mass.-based Firefly BioWorks for £18.5 million ($28 million) in cash.

Founded in 2010, Firefly has developed a multiplex assay biomarker-detection platform based on a proprietary technology called optical liquid stamping, which combines photolithography with microfluidics. The company's first products allow for the detection of cellular and circulating microRNAs.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

Aug
07
Sponsored by
Qiagen

This webinar will present the results of an evaluation of a web-based variant interpretation software system for clinical next-generation sequencing.